Key terms
About HCM
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest HCM news
Apr 05
7:00am ET
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
Apr 02
6:59am ET
New Hope in Advanced Endometrial Cancer Treatment
Apr 02
5:15am ET
Hutchmed, Innovent announce fruquintinib and sintilimab NDA accepted by NMPA
Mar 28
7:01am ET
HUTCHMED’s Savolitinib sNDA Under Review in China
Mar 22
6:59am ET
HUTCHMED Advances Sovleplenib Trial in China
Feb 28
4:55pm ET
HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential
Feb 06
11:36pm ET
Maintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit Upside
Feb 02
9:02am ET
Hutchmed licenses IMG-007 and IMG-004 to Inmagene
Feb 02
5:13am ET
Hutchmed announces Inmagene licenses two drug candidates from the company
Jan 30
5:18am ET
Hutchmed announces marketing approval of Elunate in Hong Kong
Jan 10
7:00pm ET
Hutchmed announces NDA acceptance in China for sovleplenib
No recent press releases are available for HCM
HCM Financials
Key terms
Ad Feedback
HCM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
HCM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range